ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1631316
Scutellarin attenuates hypoxia-induced retinal neovascularization through bidirectional modulation of the VEGF/Ang/Tie2 pathway
Provisionally accepted
- School of Ophthalmology, Chengdu University of Traditional Chinese Medicine, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Scutellarin (SCU), a flavonoid with established pharmacological activity, exhibits anti-angiogenic and vascular-stabilizing effects in ischemic ocular diseases. This study investigated its bidirectional modulation of the vascular endothelial growth factor(VEGF)/Angiopoietin (Ang)/Tie2 signaling pathway in retinal neovascularization (RNV) under hypoxic conditions and compared its efficacy with Faricimab, a dual-target angiogenesis inhibitor. A CoCl₂-induced hypoxic model in rat retinal microvascular endothelial cells (rRMECs) was used to evaluate proliferation, migration, and tube formation. Network pharmacology and molecular docking were employed to predict SCU targets and key signaling pathways. Western blotting and qRT-PCR validated its regulatory effects at the molecular level.SCU significantly and dose-dependently suppressed rRMEC proliferation, migration, and tube formation under hypoxia, with effects comparable to those of Faricimab at higher concentrations. Network pharmacology identified 43 overlapping targets between SCU and RNV. Pathway enrichment analysis indicated involvement of VEGF, MAPK, and Ras signaling. Molecular docking showed strong binding of SCU to VEGF-A, Ang2, Tie2, and Vascular endothelial protein tyrosine phosphatase(VE-PTP). SCU downregulated pro-angiogenic factors (VEGF-A, Ang2, HIF-1α, VE-PTP) and upregulated vascular stability-related proteins (Ang1, Tie2, vascular endothelial cadherin (VE-cadherin)) at both mRNA and protein levels. These results suggest that SCU exerts a dual regulatory effect on retinal neovascularization by simultaneously inhibiting pathological angiogenesis and enhancing vascular stabilization via the VEGF/Ang/Tie2 signaling pathway. Its mode of action complements and extends the mechanism of Faricimab, supporting its potential as a promising natural candidate for retinal vascular disease therapy.
Keywords: Scutellarin, Retinal Neovascularization, VEGF/Ang/Tie2 signaling pathway, Bidirectional regulation, Faricimab, hypoxia
Received: 19 May 2025; Accepted: 18 Sep 2025.
Copyright: © 2025 Ding, Wang, Liu, Zhang, Wang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Fuwen Zhang, wwei970315@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.